[Form 4] AtriCure, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider sale by AtriCure officer: Justin J. Noznesky, Chief Marketing & Strategy Officer and director, sold 3,000 shares of AtriCure, Inc. (ATRC) common stock on 09/12/2025 at a weighted average price of $36.30 per share. After the transaction he beneficially owned 83,964 shares. The Form 4 discloses the sale price range ($36.28–$36.36) and states the reported price is a weighted average; the filer offers to provide detailed trade-by-trade information on request. The form is signed and dated 09/16/2025.

Insights

Securities Analyst

TL;DR: Routine, small insider sale by an officer reducing holdings modestly; no other material events disclosed.

The reported sale of 3,000 shares at a weighted average of $36.30 reduces the reporting person’s beneficial holdings to 83,964 shares. The disclosure follows Section 16 reporting requirements and includes a price range for the trades. There is no indication of additional transactions, derivative activity, or change in role. From a disclosure perspective, the filing is complete and conforms to Form 4 requirements.

Corporate Governance Expert

TL;DR: Filing documents a standard officer sale with clear pricing and an offer to supply trade details; governance implications appear routine.

The Form 4 identifies the reporting person’s relationship to the issuer (Officer and Director) and specifies the transaction date, number of shares sold, weighted average price, and post-transaction beneficial ownership. The explanation clarifies the execution price range and the signer attests to accuracy. There are no statements of amendments, derivative positions, or other governance actions reflected in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Noznesky Justin J

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Mktg & Strategy Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		S		3,000	D	$36.3(1)	83,964	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $36.28 to $36.36 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Justin J. Noznesky	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Justin J. Noznesky report for ATRC?

The filer reported a sale of 3,000 shares of AtriCure (ATRC) common stock on 09/12/2025.

At what price were the ATRC shares sold on the Form 4?

The shares were sold at a weighted average price of $36.30 per share, with individual trade prices ranging from $36.28 to $36.36.

How many ATRC shares does the reporting person own after the transaction?

After the sale the reporting person beneficially owned 83,964 shares of ATRC common stock.

What is the reporting person’s role at AtriCure noted on the Form 4?

The Form 4 lists Justin J. Noznesky as a Director and as the company’s Chief Marketing & Strategy Officer.

When was the Form 4 signed and filed?

The form bears the reporting person’s signature dated 09/16/2025.